Please contact us by using the Inquiry Form. We will ask for more details by e-mail, so just a brief description is sufficient. You can also contact us from the page that appears by clicking on the structural formula.
SCHEM No. | Structure | Compound Name | Price (JPY) | Purity | Stock(mg) |
---|---|---|---|---|---|
06451 | Cyclic(-NH-PEG14-) | 97,200/0.1mg | >90% | 0 | |
06452 | Cyclic(-NH-PEG13-) | 84,900/0.1mg | >90% | 0 | |
06507 | Cyclic(-NH-PEG12-) | 84,900/0.1mg | >90% | 0 | |
06506 | Cyclic(-NH-PEG11-) | 84,900/0.1mg | >90% | 0 | |
06457 | Cyclic(-PEG4-N-)-CO-PEG11-COOH | 71,500/0.1mg | >95% | 13.3 | |
06505 | Cyclic(-NH-PEG10-) | 84,900/0.1mg | >90% | 0 | |
06504 | Cyclic(-NH-PEG9-) | 84,900/0.1mg | >90% | 0 | |
06503 | Cyclic(-NH-PEG8-) | 84,900/0.1mg | >90% | 0 | |
06502 | Cyclic(-NH-PEG7-) | 84,900/0.1mg | >90% | 0 | |
06501 | Cyclic(-NH-PEG6-) | 84,900/0.1mg | >90% | 0 | |
06376 | Cyclic(-NH-PEG5-) | 80,100/0.7mg | >90% | 6.0 | |
06385 | Cyclic(-NH-PEG4-) | inquire | >90% | 0 | |
03689 | tert-Butyl (2S)-2-[(1R,2R)-3-[[(1S)-1-benzyl-2-oxo-2-[2-(2-prop-2-ynoxyethoxy)ethylamino]ethyl]amino]-1-methoxy-2-methyl-3-oxo-propyl]pyrrolidine-1-carboxylate | 133,000/0.1mg | >95% | 206.2 | |
06388 | Cyclic(-NH-PEG3-) | 101,000/0.1mg | >90% | 0 | |
05474 | Mono-6-(N3-PEG3-NH)-beta-cyclodextrin | 67,300/0.5mg | >90% | 0.2 | |
05407 | Mono-6-(NH2-PEG3-NH)-gamma-cyclodextrin | 72,700/25mg | >90% | 81.5 | |
05406 | Mono-6-(NH2-PEG3-NH)-alpha-cyclodextrin | 72,700/25mg | >90% | 50.0 | |
03855 | Peptide intermediate | 133,000/0.1mg | >95% | 2.0 | |
03156 | Mono-6-(NH2-PEG3-NH)-beta-cyclodextrin | 72,700/25mg | >90% | 491.9 | |
02648 | Mono-2-(NH2-PEG3-NH)-beta-cyclodextrin | 72,700/25mg | >90% | 35.5 | |
01950 | Trt-PEG3-NH-PEG2-OH | 64,900/7.5mg | >95% | 230.0 | |
01133 | OH-Et-NH-PEG3-NH-Et-OH | 66,100/50mg | >95% | 2,530.0 | |
05967 | 2-[4-(1,1-dioxo-6'-piperazin-1-yl-spiro[2,1-ramda--benzoxathiole-3,9'-xanthene]-3'-yl)piperazin-1-yl]acetic acid | 68,800/0.1mg | >95% | 0 | |
05915 | (E)-4-[2-[(5-bromoquinoxalin-6-yl)amino]-4,5-dihydroimidazol-1-yl]-4-oxo-but-2-enoic acid | 68,800/0.1mg | >95% | 26.0 | |
05846 | Doxycycline N-monodesmethyl | 64,000/0.7mg | >95% | 38.3 | |
05685 | Per-6-NH-allyl-gamma-cyclodextrin | 64,000/5mg | >90% | 46.3 | |
05684 | Per-6-NH-allyl-beta-cyclodextrin | 64,000/5mg | >90% | 60.8 | |
05680 | Mono-6-NH-allyl-beta-cyclodextrin | 66,100/50mg | >90% | 175.0 | |
05679 | Mono-6-NH-allyl-alpha-cyclodextrin | 72,700/25mg | >90% | 165.2 | |
05522 | Boc-AA2-OH | 70,000/0.1mg | >95% | 0.1 | |
05497 | tert-butyl (2S)-2-(2-hydroxypropyl)pyrrolidine-1-carboxylate | 64,900/7.5mg | >95% | 86.9 | |
05486 | Mono-6-(N3-C4-NH)-beta-cyclodextrin | 64,600/0.5mg | >90% | 0.1 | |
05217 | Mono-6-(NH2-C4-NH)-gamma-cyclodextrin | 72,700/25mg | >90% | 86.2 | |
05216 | Mono-6-(NH2-C3-NH)-gamma-cyclodextrin | 72,700/25mg | >90% | 89.8 | |
05215 | Mono-6-(NH2-C2-NH)-gamma-cyclodextrin | 72,700/25mg | >90% | 78.9 | |
05212 | Mono-6-(NH2-C4-NH)-alpha-cyclodextrin | 72,700/25mg | >90% | 921.7 | |
05211 | Mono-6-(NH2-C3-NH)-alpha-cyclodextrin | 72,700/25mg | >90% | 56.9 | |
05210 | Mono-6-(NH2-C2-NH)-alpha-cyclodextrin | 72,700/25mg | >90% | 62.8 | |
04983 | Mono-6-(NH2-C2-NH)-beta-cyclodextrin | 72,700/25mg | >90% | 261.0 | |
04974 | 2-Chloro-5-(ethylaminomethyl)pyridine | 63,400/50mg | >95% | 1,000.0 | |
04940 | Boc-Me-L-Glu(OMe)-OH | inquire | >95% | 3.8 | |
04856 | N3',N6'-dimethyl-N3',N6'-bis[2-(methylamino)ethyl]-1,1-dioxo-spiro[2,1-ramda-benzoxathiole-3,9'-xanthene]-3',6'-diamine | 64,200/0.5mg | >95% | 7.9 | |
04847 | 3',6'-di(piperazin-1-yl)spiro[2,1-ramda-benzoxathiole-3,9'-xanthene] 1,1-dioxide | 64,200/0.5mg | >90% | 16.0 | |
04793 | Mono-6-(NHTrt-C6-NH)-beta-cyclodextrin | 68,400/0.4mg | >95% | 1.4 | |
04792 | Mono-6-(NH2-C6-NH)-beta-cyclodextrin | inquire | >95% | 60.4 | |
04784 | Mono-6-(NHTrt-C3-NH)-beta-cyclodextrin | 68,800/0.2mg | >95% | 4.9 | |
03517 | Fmoc-NMe-L-Leu(4-OH)-OH | 65,700/0.4mg | >95% | 11.9 | |
03516 | NMe-L-Leu(4-OH)-OH | 76,000/0.1mg | >90% | 0 | |
03515 | Me-L-Asp(OMe)-OH | 66,300/25mg | >95% | 90.0 | |
03513 | Boc-NMe-L-Asp(OMe)-OtBu | 63,400/50mg | >95% | 0 | |
03223 | Heptakis-6-(OH-C2-NH)-beta-cyclodextrin | 75,000/2.5mg | <80% | 85.7 | |
03207 | beta-cyclodextrin pentakis-(6-NH-Et-NH2 deoxy)-6-6'-ethylenediamino dideoxy | 82,800/0.7mg | >80% | 78.9 | |
03193 | Heptakis-6-(NH2-C2-NH)-beta-cyclodextrin | 82,200/0.2mg | >90% | 29.5 | |
03153 | Mono-6-(NH2-C4-NH)-beta-cyclodextrin | 72,700/25mg | >90% | 562.5 | |
02704 | Mono-2-(NH2-C4-NH)-gamma-cyclodextrin | 72,700/25mg | >90% | 15.4 | |
02650 | Mono-2-(NH2-C3-NH)-gamma-cyclodextrin | 72,700/25mg | >90% | 10.7 | |
02649 | Mono-2-(NH2-C2-NH)-gamma-cyclodextrin | 72,700/25mg | >90% | 21.9 | |
02576 | 9H-fluoren-9-ylmethyl 4-nitrosopiperazine-1-carboxylate | 66,300/2.5mg | >95% | 629.9 | |
02473 | Mono-2-(NH2-C4-NH)-beta-cyclodextrin | 72,700/25mg | >90% | 56.6 | |
02464 | Mono-2-(NH2-C3-NH)-beta-cyclodextrin | 72,700/25mg | >90% | 61.5 | |
02463 | Mono-2-(NH2-C2-NH)-beta-cyclodextrin | 72,700/25mg | >90% | 68.7 | |
02461 | Mono-2-(NH2-C4-NH)-alpha-cyclodextrin | 72,700/25mg | >90% | 1,651.8 | |
02460 | Mono-2-(NH2-C3-NH)-alpha-cyclodextrin | 72,700/25mg | >90% | 81.7 | |
02459 | Mono-2-(NH2-C2-NH)-alpha-cyclodextrin | 72,700/25mg | >90% | 46.2 | |
02334 | Fmoc-D-beta-Pro-OH | inquire | >95% | 0 | |
01917 | 2-[(2S)-1-Fmoc-pyrrolidin-2-yl]-2-oxo-ethanediazonium | inquire | >95% | 0 | |
01853 | N-Piperidin-2-ylmethyl-2,5-bis-(2,2,2-trifluoro-ethoxy)-benzamide | 64,000/5mg | >95% | 246.0 | |
00912 | (4-Acetylamino-butyl)-(3-acetylamino-propyl)-carbamic acid tert-butyl ester | 64,900/75mg | >95% | 1,650.0 | |
00532 | Cholesteryl 3beta-carboxyamidoethylene-N-hydroxyethylamine | 64,900/7.5mg | >95% | 27.6 | |
00521 | 1-Benzyl-pyrrolidine-2-carboxylic acid (2-benzoyl-phenyl)-amide | 72,300/25mg | >95% | 0 | |
00182 | 1-Boc-1H-pyrrole-2-carboxylic acid | inquire | >95% | 0 | |
00120 | N-Bn-L-Proline | inquire | >95% | 0.1 | |
00075 | Boc-Piperazine | inquire | >95% | 542.6 |